Buontempo P J, Cox S, Wright-Minogue J, DeMartino J L, Skelton A M, Ferrari E, Albin R, Rozhon E J, Girijavallabhan V, Modlin J F, O'Connell J F
Department of Antiviral Chemotherapy, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
Antimicrob Agents Chemother. 1997 Jun;41(6):1220-5. doi: 10.1128/AAC.41.6.1220.
SCH 48973 is a novel molecule with potent, selective, antienterovirus activity. In assays of the cytopathic effect against five picornaviruses, SCH 48973 had antiviral activity (50% inhibitory concentrations [IC50s]) of 0.02 to 0.11 microg/ml, with no detectable cytotoxicity at 50 microg/ml. SCH 48973 inhibited 80% of 154 recent human enterovirus isolates at an IC50 of 0.9 microg/ml. The antiviral activity of SCH 48973 is derived from its specific interaction with viral capsid, as confirmed by competition binding studies. The affinity constant (Ki) for SCH 48973 binding to poliovirus was 8.85 x 10(-8) M. In kinetic studies, a maximum of approximately 44 molecules of SCH 48973 were bound to poliovirus capsid. SCH 48973 demonstrated efficacy in a murine poliovirus model of enterovirus disease. SCH 48973 increased the survival of infected mice when it was administered orally at dosages of 3 to 20 mg/kg of body weight/day. Oral administration of SCH 48973 also reduced viral titers in the brains of infected mice. On the basis of its in vitro and in vivo profiles, SCH 48973 represents a potential candidate for therapeutic intervention against enterovirus infections.
SCH 48973是一种具有强效、选择性抗肠道病毒活性的新型分子。在针对五种小核糖核酸病毒的细胞病变效应检测中,SCH 48973具有抗病毒活性(50%抑制浓度[IC50]),为0.02至0.11微克/毫升,在50微克/毫升时未检测到细胞毒性。在IC50为0.9微克/毫升时,SCH 48973抑制了154株近期人类肠道病毒分离株中的80%。竞争结合研究证实,SCH 48973的抗病毒活性源于其与病毒衣壳的特异性相互作用。SCH 48973与脊髓灰质炎病毒结合的亲和常数(Ki)为8.85×10^(-8) M。在动力学研究中,最多约44个SCH 48973分子与脊髓灰质炎病毒衣壳结合。SCH 48973在肠道病毒疾病的小鼠脊髓灰质炎病毒模型中显示出疗效。当以3至20毫克/千克体重/天的剂量口服给药时,SCH 48973提高了感染小鼠的存活率。口服SCH 48973还降低了感染小鼠大脑中的病毒滴度。基于其体外和体内特性,SCH 48973是治疗肠道病毒感染的潜在候选药物。